We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis

By LabMedica International staff writers
Posted on 29 Apr 2025

Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. More...

However, by this time, the brain has already undergone significant and irreversible damage. Additionally, diagnosis can be challenging and often inaccurate because the disease manifests in various forms, with symptoms overlapping those of other disorders. Researchers have now identified a biomarker in spinal fluid that enables a reliable diagnosis at an earlier stage and provides insights into disease progression and the effects of therapy.

Parkinson’s disease is marked by the loss of dopaminergic nerve cells in the brain, leading to progressively worsening motor impairments. While dopamine supplements can temporarily compensate for the loss and alleviate symptoms, they do not address the underlying cause. A key factor in the development of Parkinson’s disease is the misfolding of the protein alpha-synuclein (αSyn) from α-helical structures to β-sheet-rich structures. These misfoldings cause the protein to become sticky, leading to the formation of larger complexes known as oligomers. The oligomers then form long fibrillar filaments, which aggregate into large Lewy bodies in the brain.

In two independent clinical cohorts comprising a total of 134 participants, researchers from the PRODI Center for Protein Diagnostics at Ruhr University Bochum (Bochum, Germany) and its spin-off biotech company betaSENSE (Bochum, Germany) demonstrated that the misfolding of αSyn in bodily fluids is a reliable biomarker for diagnosing Parkinson’s disease, with sensitivity and specificity exceeding 90 percent. The study, which used cerebrospinal fluid samples from patients at Parkinson’s centers in Germany, employed betaSENSE’s patented iRS (immuno-infrared sensor) technology. This technology has already been successfully applied in diagnosing Alzheimer’s disease. The findings, published in EMBO Molecular Medicine, revealed that misfolding of the biomarker Aβ can predict the risk of Alzheimer’s dementia with high accuracy, up to 17 years before a clinical diagnosis. Beyond diagnostic applications, this technology can also aid in the development of new therapeutic agents and validate their effectiveness in clinical trials.

Related Links:
Ruhr University Bochum
betaSENSE


New
Gold Member
Latex Test
SLE-Latex Test
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Respiratory Infections Test
STANDARD Q Adeno Respi Ag Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.